Northern Trust Corp purchased a new stake in Strongbridge Biopharma plc (NASDAQ:SBBP) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 204,519 shares of the biotechnology company’s stock, valued at approximately $1,462,000. Northern Trust Corp owned 0.58% of Strongbridge Biopharma as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Schwab Charles Investment Management Inc. acquired a new position in Strongbridge Biopharma during the 2nd quarter valued at about $332,000. Rhumbline Advisers acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $154,000. State of Wisconsin Investment Board acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $114,000. Bank of New York Mellon Corp acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $331,000. Finally, Teachers Advisors LLC acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $297,000. 57.53% of the stock is owned by institutional investors and hedge funds.
Shares of Strongbridge Biopharma plc (NASDAQ SBBP) opened at $6.30 on Tuesday. The company has a current ratio of 4.70, a quick ratio of 4.61 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma plc has a fifty-two week low of $2.00 and a fifty-two week high of $8.85.
COPYRIGHT VIOLATION NOTICE: “Northern Trust Corp Purchases Shares of 204,519 Strongbridge Biopharma plc (SBBP)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/05/northern-trust-corp-purchases-shares-of-204519-strongbridge-biopharma-plc-sbbp.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
What are top analysts saying about Strongbridge Biopharma plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Strongbridge Biopharma plc and related companies.